London, UK (PRWEB) January 16, 2015
Dendritic cell vaccines (DCVs) are increasingly being utilised as both prophylactic and therapeutic agents for the treatment of cancer, with the treatment aiming at bolstering the immune response against the indication. Besides developing anti-tumour immunity, dendritic cell vaccines also activate T-helper cells and are involved in the differentiation of T-cell into cytotoxic T-lymphocytes which are chiefly responsible for detecting and eliminating cancerous cells.
The creation of large-scale dendrite cell growth facilities have almost solved the problem relating to the low availability of dendrite cells; the expression of tumour-specific antigens is another issue that is expected to be settled using mRNA-based gene transfections. The potential of dendrite cells is expected to increase owing to their improved antigen-presenting capabilities. This could help lower the current mortality rates, boost longevity and effectively compete with other therapeutics in the same categories of cancer.
Realising the high potential of dendritic cell cancer vaccines, pharma companies are investing huge sums of their revenues in the R&D of such vaccines. However, a lot of people have raised concerns about the immunotoxicity of dendritic cell cancer vaccines – a primary focus of the R&D segment. A number of products are currently at different phases of clinical trials and expected to come into the market in the oncoming years. The research is mainly focused on decreasing the immunotoxicity of dendritic cell cancer vaccines alongside improving their efficacy and safety profiles, and thus relieving the necessities of patients with cancer.
New cutting-edge report “Dendritic Cell Cancer Vaccine Market & Clinical Insight” worked out by Kuick Research is now available at MarketPublishers.com.
Title: Dendritic Cell Cancer Vaccine Market & Clinical Insight
Published: January, 2015
Price: US$ 1,800.00
The report provides an indispensible guide to the world dendritic cell cancer vaccine marketplace. It provides a deep overview of dendritic cell cancer vaccines as well as their mechanisms. The study presents a deep overview of the current market and commercialisation scenario alongside accurate insights into the clinical pipeline; examines the market dynamics including key market and commercialisation challenges & drivers and future prospects. The report provides an up-close look at the dendritic cell cancer vaccine development pipeline by indication, phase and company. It reviews the 52 dendritic cell cancer vaccine candidates in clinical development, sheds light on the 13 dendritic cell cancer vaccines in the second phase of clinical trials, as well as discusses the three marketed dendritic cell cancer vaccines – Provenge, CreaVax and DC-CIK. The competitive landscape is also analysed including profiles of the top 10 market players.
Companies mentioned: Activartis, 3M Company, Batavia Bioservices, Creagene, Dendreon, Merck, ImmunoCellular Therapeutics, Northwest Biotherapeutics, Glaxo Smith Kline, and Tella Incorporation.
- Comprehensive overview of dendritic cell cancer vaccines and mechanisms.
- In-depth overview of the market for dendritic cell cancer vaccines.
- Examination of the market dynamics, including key growth propellers, challenges and future projections.
- All-round assessment of the dendritic cell cancer vaccines pipeline based on indication, phase, and company.
- Review of the 52 dendritic cell cancer vaccines presently in development stage.
- Up-close look at the 13 dendritic cell cancer vaccines in phase II.
- Comprehensive analysis of the 3 marketed dendritic cell cancer vaccines.
- Detailed analysis of the competition and the leading 10 players.
More new studies by the publisher can be found at Kuick Research page.